F-star Therapeutics Stock News

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next-gene

Equities analysts expect F-star Therapeutics, Inc. (NASDAQ:FSTX) to report $11.78 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for F-star Therapeutics earnings, with estimates ranging from $330,000.00 to $17.50 million. The firm is scheduled to report its next quarterly earnings report on Monday, April 4th. According to []

First-in-Human Study of Company''s CD137/PD-L1 Tetravalent Bispecific Antibody Expands into Tumor Specific IndicationsCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 07, 2021, taking place onli…

First-in-Human Study of Companys CD137/PD-L1 Tetravalent Bispecific Antibody Expands into Tumor Specific Indications First-in-Human Study of Companys CD137/PD-L1 Tetravalent Bispecific Antibody Expands into Tumor Specific Indications

First-in-Human Study of Company's CD137/PD-L1 Tetravalent Bispecific Antibody Expands into Tumor Specific Indications First-in-Human Study of Company's CD137/PD-L1 Tetravalent Bispecific Antibody Expa

Marker Therapeutics (NASDAQ:MRKR) and F-star Therapeutics (NASDAQ:FSTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends. Analyst Recommendations This is a summary of current recommendations and price targets for Marker Therapeutics []

F-star Therapeutics, Inc. (NASDAQ:FSTX) has been given an average rating of Buy by the eight analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued []

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that it will host an R&D Day webinar on Monday, December 6, 2021, from 8:00 a.m. to 10:00 a.m. ET.

Wall Street brokerages expect that F-star Therapeutics, Inc. (NASDAQ:FSTX) will post $11.78 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for F-star Therapeutics’ earnings. The lowest sales estimate is $330,000.00 and the highest is $17.50 million. The firm is scheduled to issue its next quarterly earnings results on […]

Vanguard Group Inc. increased its holdings in shares of F-star Therapeutics, Inc. (NASDAQ:FSTX) by 46.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 773,215 shares of the companys stock after purchasing an additional 244,726 shares during the period. Vanguard Group Inc. owned approximately 3.99% of F-star Therapeutics []

F-star Therapeutics, Inc. (NASDAQ:FSTX) was the target of a significant growth in short interest during the month of October. As of October 29th, there was short interest totalling 813,900 shares, a growth of 291.1% from the October 14th total of 208,100 shares. Based on an average daily trading volume, of 210,200 shares, the short-interest ratio []

Zacks Investment Research downgraded shares of F-star Therapeutics (NASDAQ:FSTX) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning, Zacks.com reports. According to Zacks, F-star Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. F-star Therapeutics []

F-star Therapeutics (NASDAQ:FSTX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Tuesday, Zacks.com reports. According to Zacks, F-star Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. F-star Therapeutics Inc., formerly known as []

F-star Therapeutics (FSTX) has been struggling lately, but the selling pressure may be coming to an end soon.